US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

BioAge Labs Inc.

4.18

-0.0200-0.48%

Volume:87.64K

Turnover:368.02K

Market Cap:149.85M

PE:-0.63

High:4.25

Open:4.21

Low:4.15

Close:4.20

Loading ...

Overview Company News Filings

BioAge Labs, Inc. (BIOA): A Bull Case Theory

Bioage Labs Is Maintained at Neutral by Citigroup

North American Morning Briefing: Stock Futures Rise on Tariff Optimism

Cautious Outlook on BioAge Labs Amid Promising Developments and High Risk

BioAge Labs, Inc.: Sell Rating Due to Discontinued Program and Uncertain Prospects

Jefferies Reaffirms Their Hold Rating on BioAge Labs, Inc. (BIOA)

BioAge Labs FY24 EPS $(6.63) Up From $(38.17) YoY

Press Release: BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024

BioArctic receives Orphan Drug Designation for exidavnemab the US

Bioarctic Receives Orphan Drug Designation for Exidavnemab the US

THOMSON REUTERS

Bioage Labs Coverage Assumed by Morgan Stanley at Underweight

BioAge Labs, Inc. (BIOA) Initiated with a Hold at William Blair

William Blair Initiates BioAge Labs at Market Perform

MT Newswires Live

U.S. RESEARCH ROUNDUP-Autodesk, Coca-Cola, NetApp

Weight-loss drug developer Metsera raises $275 million in US IPO

BioAge Labs: Strategic Shifts and Developmental Progress Support Hold Rating Amidst Inherent Risks

BioAge Labs Terminates Azelapra Development

MT Newswires Live

BioAge Labs provides updates, terminates development of azelaprag

BRIEF-Bioage Labs Announces Company Updates On APJ, NLRP3, And Platform Programs

Bioage Labs: Nomination of Nlrp3 Inhibitor Bge-102 as a Development Candidate, With Initial Ph1 Clinical Data Anticipated by End of 2025

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BIOA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BIOA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BIOA\",,,,,undefined,":{"symbol":"BIOA","market":"US","secType":"STK","nameCN":"BioAge Labs Inc.","latestPrice":4.18,"timestamp":1745421611726,"preClose":4.2,"halted":0,"volume":87642,"delay":0,"floatShares":23819976,"shares":35850037,"eps":-6.629269,"marketStatus":"Trading","change":-0.02,"latestTime":"04-23 11:21:27 EDT","open":4.21,"high":4.25,"low":4.153,"amount":368022.28992480005,"amplitude":0.023095,"askPrice":4.18,"askSize":35,"bidPrice":4.16,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-6.629269,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1745438400000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1727323200000,"exchange":"NASDAQ","adjPreClose":4.2,"preHourTrading":{"tag":"盘前","latestPrice":4.12,"preClose":4.2,"latestTime":"09:28 EDT","volume":313,"amount":1308.8800815,"timestamp":1745414880134},"postHourTrading":{"tag":"盘后","latestPrice":4.11,"preClose":4.2,"latestTime":"18:41 EDT","volume":1086,"amount":4499.82,"timestamp":1745361716853},"volumeRatio":1.148303,"impliedVol":0.9044,"impliedVolPercentile":0.7347},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BIOA\",,,,,undefined,":{"symbol":"BIOA","floatShares":23819976,"roa":"-25.44%","roe":"-50.35%","lyrEps":-6.629269,"volumeRatio":1.148303,"shares":35850037,"dividePrice":0,"high":4.25,"amplitude":0.023095,"preClose":4.2,"low":4.153,"week52Low":2.88,"pbRate":"0.46","week52High":26.62,"institutionHeld":0,"latestPrice":4.18,"committee":0.481481,"eps":-6.629269,"divideRate":0,"volume":87642,"delay":0,"ttmEps":-6.629269,"open":4.21,"prevYearClose":5.79,"prevWeekClose":3.87,"prevMonthClose":3.76,"prevQuarterClose":3.76,"fiveDayClose":3.75,"twentyDayClose":4.28,"sixtyDayClose":5.37},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BIOA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2529274335","title":"BioAge Labs, Inc. (BIOA): A Bull Case Theory","url":"https://stock-news.laohu8.com/highlight/detail?id=2529274335","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529274335?lang=en_us&edition=fundamental","pubTime":"2025-04-22 01:02","pubTimestamp":1745254929,"startTime":"0","endTime":"0","summary":"We came across abullish thesison BioAge Labs, Inc.  on Substack by Ragnarok Research. In this article, we will summarize the bulls’ thesis on BIOA. BioAge Labs, Inc. 's share was trading at $3.87 as of April 17th.BioAge Labs, Inc.  is not on our list of the30 Most Popular Stocks Among Hedge Funds. As per our database, 13 hedge fund portfolios held BIOA at the end of the fourth quarter which was 17 in the previous quarter. While we acknowledge the risk and potential of BIOA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than BIOA but that trades at less than 5 times its earnings, check out our report about thecheapest AI stock.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bioage-labs-inc-bioa-bull-170209007.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BIOA"],"gpt_icon":0},{"id":"2521824775","title":"Bioage Labs Is Maintained at Neutral by Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2521824775","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521824775?lang=en_us&edition=fundamental","pubTime":"2025-03-24 22:51","pubTimestamp":1742827860,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BIOA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 24, 2025 10:51 ET (14:51 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIOA"],"gpt_icon":0},{"id":"2521710692","title":"North American Morning Briefing: Stock Futures Rise on Tariff Optimism","url":"https://stock-news.laohu8.com/highlight/detail?id=2521710692","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521710692?lang=en_us&edition=fundamental","pubTime":"2025-03-24 18:25","pubTimestamp":1742811900,"startTime":"0","endTime":"0","summary":"Stock futures jumped Monday, boosted by relief that the next barrage of tariffs could be narrower than previously feared.The White House is narrowing its approach to tariffs  set to take effect on April 2.It will likely leave out tariffs on specific industries while applying reciprocal charges on some major trading partners.This week's full slate of data releases  could easily reignite volatility in a stock market already feeling uneasy about the economy, according to market analysts.GameStop, Dollar Tree, and Lululemon  are all due to report earnings during the week.Azek stock  rose 18% after it agreed to be acquired by Australian-listed James Hardie Industries.MicroStrategy rose 4.7%. The major Bitcoin investor lowered the price of its coming preferred stock offering.In a filing Friday it said it would sell perpetual preferred stock at $85 a share, 15% below the $100 price it originally expected. The company, however, increased the size of its offering and now will sell 8.5 million s","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATIP","BK4144","BK4196","BK4107","BK4539","BIOA","BK4077","BK4111","BK4581","BK4121","BK4561","ET","OP.USD.HKCC","AFG","AERG","BK4585","BK4187","BK4587","BZFD","AKYA","BK4590","BK4007","BK4117","CFNB","BK4588","BK4164"],"gpt_icon":0},{"id":"2521078582","title":"Cautious Outlook on BioAge Labs Amid Promising Developments and High Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2521078582","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521078582?lang=en_us&edition=fundamental","pubTime":"2025-03-24 02:15","pubTimestamp":1742753728,"startTime":"0","endTime":"0","summary":"Samantha Semenkow, an analyst from Citi, maintained the Hold rating on BioAge Labs, Inc. (BIOA – Research Report). The associated price target was ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/cautious-outlook-on-bioage-labs-amid-promising-developments-and-high-risk?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/cautious-outlook-on-bioage-labs-amid-promising-developments-and-high-risk?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BIOA","BK4007"],"gpt_icon":0},{"id":"2521785874","title":"BioAge Labs, Inc.: Sell Rating Due to Discontinued Program and Uncertain Prospects","url":"https://stock-news.laohu8.com/highlight/detail?id=2521785874","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521785874?lang=en_us&edition=fundamental","pubTime":"2025-03-24 02:15","pubTimestamp":1742753711,"startTime":"0","endTime":"0","summary":"In a report released on March 21, Michael Ulz from Morgan Stanley maintained a Sell rating on BioAge Labs, Inc. (BIOA – Research Report), with a pr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/bioage-labs-inc-sell-rating-due-to-discontinued-program-and-uncertain-prospects?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/bioage-labs-inc-sell-rating-due-to-discontinued-program-and-uncertain-prospects?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BIOA"],"gpt_icon":0},{"id":"2521286342","title":"Jefferies Reaffirms Their Hold Rating on BioAge Labs, Inc. (BIOA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2521286342","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521286342?lang=en_us&edition=fundamental","pubTime":"2025-03-21 20:35","pubTimestamp":1742560535,"startTime":"0","endTime":"0","summary":"Jefferies analyst Roger Song maintained a Hold rating on BioAge Labs, Inc. (BIOA – Research Report) yesterday and set a price target of $7.00. The ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jefferies-reaffirms-their-hold-rating-on-bioage-labs-inc-bioa?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jefferies-reaffirms-their-hold-rating-on-bioage-labs-inc-bioa?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BIOA"],"gpt_icon":0},{"id":"2521499424","title":"BioAge Labs FY24 EPS $(6.63) Up From $(38.17) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2521499424","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521499424?lang=en_us&edition=fundamental","pubTime":"2025-03-21 04:33","pubTimestamp":1742502793,"startTime":"0","endTime":"0","summary":"Full Year 2024 Financial ResultsResearch and development expenses were $59.0 million for the year ended December 31, 2024, compared to $33.9 million for the same period in 2023. The $25.1 million increase in research and","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44425927/bioage-labs-fy24-eps-6-63-up-from-38-17-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"BioAge Labs FY24 EPS $(6.63) Up From $(38.17) YoY","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIOA"],"gpt_icon":0},{"id":"2521991774","title":"Press Release: BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2521991774","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521991774?lang=en_us&edition=fundamental","pubTime":"2025-03-21 04:30","pubTimestamp":1742502600,"startTime":"0","endTime":"0","summary":"BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024. Advancement of oral, brain-penetrant NLRP3 inhibitor BGE-102, with initial clinical data expected 2H25. Progression of preclinical next-generation APJ agonists for obesity. New platform partnerships with Novartis and Lilly to discover and develop novel therapies for conditions driven by metabolic aging. RICHMOND, Calif., March 20, 2025  -- BioAge Labs, Inc. , a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging, today provided financial results for the full year ended December 31, 2024 and business updates for the fourth quarter ended December 31, 2024.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BIOA"],"gpt_icon":0},{"id":"2520096935","title":"BioArctic receives Orphan Drug Designation for exidavnemab the US","url":"https://stock-news.laohu8.com/highlight/detail?id=2520096935","media":"PR Newswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520096935?lang=en_us&edition=fundamental","pubTime":"2025-03-18 01:54","pubTimestamp":1742234040,"startTime":"0","endTime":"0","summary":"STOCKHOLM, March 17, 2025 /PRNewswire/ -- BioArctic AB   announced today that the US FDA Office of Orphan Products Development  hasgranted orphan drug designation  to exidavnemab for the treatment of Multiple System Atrophy , providing incentives for the development of treatments for rare diseases with a high medical need.Multiple System Atrophy  is a rapidly progressive and fatal rare disease affecting the central and autonomic nervous systems. MSA is characterized by pathological alpha-synuclein aggregation, that causes gradual damage to nerve cells in the brain. This affects balance, movement and the autonomic nervous system, which controls several basic functions, such as breathing, digestion and bladder control. Currently there is no cure and no available treatment to slow its progression.About MSA Multiple System Atrophy  is a rapidly progressive and fatal rare disease affecting the central and autonomic nervous systems. MSA is a synucleinopathy, a group of neurodegenerative dise","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/bioarctic-receives-orphan-drug-designation-175400532.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bioarctic-receives-orphan-drug-designation-175400532.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2125909916.SGD","LU2211815571.USD","BIOA","LU0728928796.USD","LU1923622291.USD","LU0757428866.USD","BK4143","MSA","BK4007","LU0053671581.USD","BRCTF","BK4183","LU1815336091.USD","ODD","LU2125909759.SGD"],"gpt_icon":0},{"id":"2520505233","title":"Bioarctic Receives Orphan Drug Designation for Exidavnemab the US","url":"https://stock-news.laohu8.com/highlight/detail?id=2520505233","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520505233?lang=en_us&edition=fundamental","pubTime":"2025-03-18 01:50","pubTimestamp":1742233802,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250317:nTUA6Z9DCY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIOA","BK4007"],"gpt_icon":0},{"id":"2517554434","title":"Bioage Labs Coverage Assumed by Morgan Stanley at Underweight","url":"https://stock-news.laohu8.com/highlight/detail?id=2517554434","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517554434?lang=en_us&edition=fundamental","pubTime":"2025-03-08 01:22","pubTimestamp":1741368120,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BIOA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 07, 2025 12:22 ET (17:22 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIOA"],"gpt_icon":0},{"id":"2517927222","title":"BioAge Labs, Inc. (BIOA) Initiated with a Hold at William Blair","url":"https://stock-news.laohu8.com/highlight/detail?id=2517927222","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517927222?lang=en_us&edition=fundamental","pubTime":"2025-03-06 06:16","pubTimestamp":1741212967,"startTime":"0","endTime":"0","summary":"BioAge Labs, Inc. (BIOA – Research Report) received a Hold rating and price target from William Blair analyst Andy Hsieh today. The company’s share...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bioage-labs-inc-bioa-initiated-with-a-hold-at-william-blair?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bioage-labs-inc-bioa-initiated-with-a-hold-at-william-blair?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BIOA","BK4007"],"gpt_icon":0},{"id":"2514032606","title":"William Blair Initiates BioAge Labs at Market Perform","url":"https://stock-news.laohu8.com/highlight/detail?id=2514032606","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514032606?lang=en_us&edition=fundamental","pubTime":"2025-02-28 20:54","pubTimestamp":1740747249,"startTime":"0","endTime":"0","summary":"William Blair Initiates BioAge Labs at Market Perform","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BIOA"],"gpt_icon":0},{"id":"2514318237","title":"U.S. RESEARCH ROUNDUP-Autodesk, Coca-Cola, NetApp","url":"https://stock-news.laohu8.com/highlight/detail?id=2514318237","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514318237?lang=en_us&edition=fundamental","pubTime":"2025-02-28 15:07","pubTimestamp":1740726458,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Autodesk, Coca-Cola, NetApp Feb 28 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Autodesk, Coca-","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nL3N3PJ0KS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTLA","TASK","CRBP","IE00BBT3K403.USD","LU1037948541.HKD","HRL","LU2506952097.USD","RUN","FOLD","LU0289960550.SGD","IOVA","RLAY","ALT","NTAP","IE00B1BXHZ80.USD","LU0965509010.AUD","KO","CARS","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","LU1992135472.HKD","ADSK","ORA","GPCR","RKT","TERN","MNST","ALHC","COGT","SJM","LU0175139822.USD","ICUI","JAMF","ARRY","IE0002141913.USD","STWD","BK4226","DUOL","LU0012050646.USD","LU0106261372.USD","NUVL","VAC","CCOI","LU0823414478.USD","PSBD","BIOA","BE"],"gpt_icon":1},{"id":"2507607306","title":"Weight-loss drug developer Metsera raises $275 million in US IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2507607306","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507607306?lang=en_us&edition=fundamental","pubTime":"2025-01-31 08:01","pubTimestamp":1738281708,"startTime":"0","endTime":"0","summary":"Weight-loss drug developer Metsera raises $275 million in US IPOJan 30 (Reuters) - Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250131:nL3N3OQ2E8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MBX","BK4007","BIOA"],"gpt_icon":0},{"id":"2507868682","title":"BioAge Labs: Strategic Shifts and Developmental Progress Support Hold Rating Amidst Inherent Risks","url":"https://stock-news.laohu8.com/highlight/detail?id=2507868682","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507868682?lang=en_us&edition=fundamental","pubTime":"2025-01-29 19:46","pubTimestamp":1738151176,"startTime":"0","endTime":"0","summary":"Analyst Samantha Semenkow from Citi maintained a Hold rating on BioAge Labs, Inc. (BIOA – Research Report) and keeping the price target at $7.00. S...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bioage-labs-strategic-shifts-and-developmental-progress-support-hold-rating-amidst-inherent-risks?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bioage-labs-strategic-shifts-and-developmental-progress-support-hold-rating-amidst-inherent-risks?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BIOA","PRGS"],"gpt_icon":0},{"id":"2506517265","title":"BioAge Labs Terminates Azelapra Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2506517265","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506517265?lang=en_us&edition=fundamental","pubTime":"2025-01-28 23:35","pubTimestamp":1738078522,"startTime":"0","endTime":"0","summary":"BioAge Labs  said Tuesday it terminated the development of azelapra after elevated levels of certain liver enzymes were recorded in the blood of some patients in a phase 2 clinical study for obesity.The company said it is developing structurally distinct APJ agonists and plans to finalize a development candidate by the end of 2025.BGE-102 is under development for the treatment of neuroinflammation and phase 1 single ascending dose data is expected by the end of the year, BioAge said.Price: 5.29, Change: -0.09, Percent Change: -1.58","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BIOA","BK4007"],"gpt_icon":0},{"id":"2506474519","title":"BioAge Labs provides updates, terminates development of azelaprag","url":"https://stock-news.laohu8.com/highlight/detail?id=2506474519","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506474519?lang=en_us&edition=fundamental","pubTime":"2025-01-28 22:15","pubTimestamp":1738073723,"startTime":"0","endTime":"0","summary":"BioAge Labs (BIOA) announced company updates for its programs and platform. Advancement of next-generation APJ agonists with discontinuation of aze...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bioage-labs-provides-updates-terminates-development-of-azelaprag?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bioage-labs-provides-updates-terminates-development-of-azelaprag?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BIOA"],"gpt_icon":0},{"id":"2506342519","title":"BRIEF-Bioage Labs Announces Company Updates On APJ, NLRP3, And Platform Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2506342519","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506342519?lang=en_us&edition=fundamental","pubTime":"2025-01-28 22:07","pubTimestamp":1738073276,"startTime":"0","endTime":"0","summary":"BRIEF-Bioage Labs Announces Company Updates On APJ, NLRP3, And Platform ProgramsJan 28 (Reuters) - BIOAGE Labs Inc BIOA.O:BIOAGE LABS ANNOUNCES COMPANY UPDATES ON APJ, NLRP3, AND PLATFORM PROGRAMSBIOA","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250128:nFWN3OO1G1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BIOA"],"gpt_icon":0},{"id":"2506516072","title":"Bioage Labs:  Nomination of Nlrp3 Inhibitor Bge-102 as a Development Candidate, With Initial Ph1 Clinical Data Anticipated by End of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2506516072","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506516072?lang=en_us&edition=fundamental","pubTime":"2025-01-28 22:06","pubTimestamp":1738073164,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250128:nFWN3OO1G1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIOA","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":70,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BIOA\",params:#limit:5,,,undefined,":[{"date":"2025-03-20","symbol":"BIOA","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2024/12","expectedEps":-0.58,"defaultRemindTime":1742500800000,"name":null,"time":"Post Market","dateTimestamp":1742443200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BIOA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BIOA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":0.75,"sell":0.25,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.75,"analysts":4,"updateTime":1740715200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BIOA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BIOA","date":"2025-04-22","current":-2.026708,"percent":0.879433,"low":-14.88445,"twenty":-10.981917,"median":-2.5773,"eighty":-2.184136,"high":-1.532635,"avg":-5.625973,"sd":4.530972,"marketCap":144117148},"quantilePoints":[{"date":"2024-09-27","current":-10.065016,"twenty":-9.996853,"median":-9.894609,"eighty":-9.328936,"marketCap":625601139},{"date":"2024-10-04","current":-11.466752,"twenty":-11.453559,"median":-10.988513,"eighty":-9.962772,"marketCap":712727458},{"date":"2024-10-11","current":-11.290848,"twenty":-11.83725,"median":-11.290848,"eighty":-10.377246,"marketCap":701793959},{"date":"2024-10-18","current":-13.247909,"twenty":-12.852074,"median":-11.505231,"eighty":-10.913754,"marketCap":823437060},{"date":"2024-10-25","current":-13.708907,"twenty":-13.699687,"median":-12.032944,"eighty":-11.062173,"marketCap":852090807},{"date":"2024-10-31","current":-14.198716,"twenty":-13.910593,"median":-12.258321,"eighty":-11.163318,"marketCap":882535413},{"date":"2024-11-08","current":-10.411209,"twenty":-13.841443,"median":-12.631325,"eighty":-11.163318,"marketCap":738550334},{"date":"2024-11-15","current":-9.850761,"twenty":-13.741177,"median":-12.203351,"eighty":-10.879672,"marketCap":698793259},{"date":"2024-11-22","current":-9.318711,"twenty":-13.704297,"median":-11.736106,"eighty":-10.071646,"marketCap":661050728},{"date":"2024-11-29","current":-9.500638,"twenty":-13.685857,"median":-11.456511,"eighty":-9.850761,"marketCap":673956274},{"date":"2024-12-06","current":-9.283336,"twenty":-13.657045,"median":-11.290848,"eighty":-9.500638,"marketCap":658541317},{"date":"2024-12-13","current":-2.319571,"twenty":-13.258776,"median":-11.073716,"eighty":-9.298497,"marketCap":164545707},{"date":"2024-12-20","current":-2.612676,"twenty":-13.247909,"median":-10.411209,"eighty":-9.141838,"marketCap":185337975},{"date":"2024-12-27","current":-2.971476,"twenty":-13.224859,"median":-10.152544,"eighty":-7.606575,"marketCap":210790579},{"date":"2025-01-03","current":-2.809763,"twenty":-13.09117,"median":-10.065016,"eighty":-3.032119,"marketCap":199318983},{"date":"2025-01-10","current":-2.572247,"twenty":-12.858367,"median":-9.894609,"eighty":-2.886577,"marketCap":182470076},{"date":"2025-01-17","current":-2.54698,"twenty":-12.632478,"median":-9.680039,"eighty":-2.714757,"marketCap":180677639},{"date":"2025-01-24","current":-2.678371,"twenty":-12.552115,"median":-9.568861,"eighty":-2.625815,"marketCap":189998311},{"date":"2025-01-31","current":-2.415588,"twenty":-12.247327,"median":-9.318711,"eighty":-2.600547,"marketCap":171356967},{"date":"2025-02-07","current":-2.309464,"twenty":-12.16927,"median":-9.263122,"eighty":-2.51868,"marketCap":163828732},{"date":"2025-02-14","current":-2.284196,"twenty":-12.012055,"median":-9.141838,"eighty":-2.417609,"marketCap":162036295},{"date":"2025-02-21","current":-2.223554,"twenty":-11.928501,"median":-8.818412,"eighty":-2.37516,"marketCap":157734447},{"date":"2025-02-28","current":-2.208393,"twenty":-11.54371,"median":-3.087708,"eighty":-2.319571,"marketCap":156658985},{"date":"2025-03-07","current":-2.269035,"twenty":-11.466752,"median":-2.971476,"eighty":-2.294303,"marketCap":160960833},{"date":"2025-03-14","current":-2.122483,"twenty":-11.446271,"median":-2.893147,"eighty":-2.269035,"marketCap":150564699},{"date":"2025-03-21","current":-2.208204,"twenty":-11.43377,"median":-2.779442,"eighty":-2.233661,"marketCap":157023162},{"date":"2025-03-28","current":-1.956126,"twenty":-11.290848,"median":-2.7188,"eighty":-2.233661,"marketCap":139098143},{"date":"2025-04-04","current":-1.714131,"twenty":-11.203915,"median":-2.693532,"eighty":-2.213447,"marketCap":121890125},{"date":"2025-04-11","current":-1.729255,"twenty":-11.131435,"median":-2.645523,"eighty":-2.198286,"marketCap":122965626},{"date":"2025-04-17","current":-1.890585,"twenty":-11.039085,"median":-2.589935,"eighty":-2.192221,"marketCap":134437638},{"date":"2025-04-22","current":-2.026708,"twenty":-10.981917,"median":-2.5773,"eighty":-2.184136,"marketCap":144117148}],"updateTime":1745398937686}}}